Related Experiment Video
Updated: Oct 6, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
Giulia Marvaso1,2, Stefania Volpe1,2, Matteo Pepa1
1Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Abstract:
After primary treatment for prostate cancer with either radical prostatectomy or radiotherapy, a significant proportion of patients are at risk of developing metastases. In recent years, a deeper understanding of the underlying biology together with improved imaging techniques and the advent of new therapeutic options including metastases-directed therapies and new drugs have revolutionized the management of low-burden metastatic disease, also known as oligometastatic state. The purpose of this narrative review is to report the recent developments in the management of hormone-sensitive oligometastatic prostate cancer patients.
Insights
Managing hormone-sensitive oligometastatic prostate cancer has advanced significantly. New therapies and imaging improve outcomes for patients with low-volume metastatic disease after initial prostate cancer treatment.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer recurrence can lead to metastases.
- Oligometastatic prostate cancer (low-burden metastatic disease) requires specialized management.
- Advances in biology, imaging, and therapeutics are transforming treatment.
Purpose of the Study:
- To review recent developments in managing hormone-sensitive oligometastatic prostate cancer.
- To highlight new therapeutic options and improved imaging techniques.
Main Methods:
- Narrative review of recent literature.
- Synthesis of current understanding in prostate cancer metastasis management.
Main Results:
- Significant progress in understanding oligometastatic prostate cancer biology.
- Emergence of effective metastases-directed therapies and novel drugs.
- Improved imaging aids in identifying and managing low-burden metastatic disease.
Conclusions:
- The management of hormone-sensitive oligometastatic prostate cancer has been revolutionized.
- Current advancements offer new hope and improved strategies for patients.
- Continued research is vital for further optimizing treatment outcomes.
